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The complexity of autoimmune diseases is a barrier to the design of strategies that can blunt autoimmunity 
without impairing general immunity. We have shown that systemic delivery of nanoparticles (NPs) coated with 
autoimmune disease-relevant peptide-major-histocompatibility-complex (pMHC) molecules triggers the 
formation and profound expansion of antigen-specific T-regulatory T-cells in different mouse models, including 
mice humanized with lymphocytes from patients, leading to resolution of a broad range of established 
autoimmune phenomena. I will highlight the engineering principles impacting biological activity, will illustrate how 
these nanomedicines interact with cognate T-cells and will describe the pharmacokinetic behavior and 
toxicological profile of this novel class of drugs, potentially useful for treating a broad spectrum of autoimmune 
conditions in a disease-specific manner.  
 
 
